Skip to main content
. 2022 Jun 30;25(8):104702. doi: 10.1016/j.isci.2022.104702

Figure 5.

Figure 5

Subgroup analysis of the in silico clinical trial of atezolizumab and nab-paclitaxel

The virtual patient population was divided into eight subgroups based on the pre-treatment values of selected characteristics, and the objective response rates in each subgroup were calculated with 95% bootstrap confidence intervals.